Prelude TherapeuticsPRLD +1.63%26 PS Ratio is 23.54 as of Jul. 07, 2026, which is 86% above its 10-year median of 12.67. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 929 Biotechnology companies, Prelude Therapeutics ranks worse than 67.81% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prelude Therapeutics's share price is $4.99.
Prelude Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.21. Hence, Prelude Therapeutics's PS Ratio for today is 23.54.
Warning Sign:
Prelude Therapeutics Inc stock PS Ratio (=23.14) is close to 1-year high of 23.16.
The historical rank and industry rank for Prelude Therapeutics's PS Ratio or its related term are showing as below:
PRLD'
s PS Ratio Range Over the Past 10 Years
Min: 7.26 Med: 12.67 Max: 50
Current: 23.53
During the past 8 years, Prelude Therapeutics's highest PS Ratio was 50.00. The lowest was 7.26. And the median was 12.67.
PRLD's PS Ratio is ranked worse than 67.81% of 929
companies
in the Biotechnology industry
Industry Median: 9.64
vs PRLD: 23.53
Prelude Therapeutics (NAS:PRLD) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Prelude Therapeutics PS Ratio Related Terms
Prelude Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prelude Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Prelude Therapeutics's Share Price of today is $4.99. Prelude Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Prelude Therapeutics (PRLD) has a PS Ratio of 23.54 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prelude Therapeutics and its competitors. This is 86% above median its historical median of 12.67. Over the past decade, Prelude Therapeutics' PS Ratio has ranged from 7.26 to 50.00. According to the industry distribution chart, Prelude Therapeutics ranks #630 out of 929 companies in the Biotechnology industry, placing it in the top 67.8%.
Is Prelude Therapeutics' PS Ratio too high?
Prelude Therapeutics' current PS Ratio of 23.54 is 86% above median its 10-year median of 12.67. Over the past 10 years, this metric has ranged from a low of 7.26 to a high of 50.00. The Biotechnology industry median PS Ratio is 9.64. Prelude Therapeutics' value of 23.54 is 144.2% above this industry median. Based on the distribution chart, Prelude Therapeutics ranks #630 out of 929 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' PS Ratio compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #630 out of 929 companies for PS Ratio. This places Prelude Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.64. Prelude Therapeutics' value of 23.54 is 144.2% above this benchmark. Historically, Prelude Therapeutics' own PS Ratio has ranged from 7.26 to 50.00 over the past decade. While the company's 10-year median is 12.67 vs. the industry median of 9.64, Prelude Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current PS Ratio of 23.54 is 144.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prelude Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current PS Ratio is 23.54, which is 86% above median its own 10-year median of 12.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current PS Ratio of 23.54. The current PS Ratio is 23.54, which is 86% above median its 10-year median of 12.67 and 144.2% above the Biotechnology industry median of 9.64. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current PS Ratio is 23.54 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score
Get the complete analysis for PRLD
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
